Commitment of Bayer and Onyx to Investigate and Develop New Molecular Targets Involved in Liver and Other Cancers

Bayer HealthCare Pharmaceuticals, Inc., and Onyx Pharmaceuticals, Inc., are committed to exploring and understanding the intriguing RAS/RAF/MEK/ERK pathway and are confident that it will soon lead to important discoveries in our fight against cancer.

Read more about:

- a A + text zoom
Site Updates
Sign up now to receive email notifications as new knowledge emerges on the role of RAF kinase in tumorigenesis. Register Now
Information for Patients
Explore the molecular basis of Hepatocellular Carcinoma (HCC) in this detailed slide kit. View Slideshow
Bayer Pharmaceuticals Healthcare Onyx Pharmaceuticals
A new path to HCC Knowledge